Research To Practice | Oncology Videos podcast

Player FM - Internet Radio Done Right

46 subscribers

추가했습니다 eight 년 전

Dr Neil Love에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Dr Neil Love 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

This Is Woman's Work with Nicole Kalil

1
The Icelandic Art of Intuition with Hrund Gunnsteinsdóttir | 307 40:34

18일 전40:34

나중에 재생

리스트

40:34

We’ve turned intuition into a buzzword—flattened it into a slogan, a gut feeling, or a vague whisper we don’t always know how to hear. But what if intuition is so much more? What if it's one of the most powerful tools we have—and we’ve just forgotten how to use it? In this episode, I’m joined by Hrund Gunnsteinsdóttir , Icelandic thought leader, filmmaker, and author of InnSæi: Icelandic Wisdom for Turbulent Times . Hrund has spent over 20 years studying and teaching the science and art of intuition through her TED Talk, Netflix documentary (InnSæi: The Power of Intuition), and global work on leadership, innovation, and inner knowing. Together, we explore what intuition really is (hint: not woo-woo), how to cultivate it in a culture obsessed with logic and overthinking, and why your ability to listen to yourself might be the most essential skill you can develop. In This Episode, We Cover: ✅ Why we’ve misunderstood intuition—and how to reclaim it ✅ Practical ways to strengthen your intuitive muscle ✅ What Icelandic wisdom teaches us about inner knowing ✅ How to use intuition during uncertainty and decision-making ✅ Why trusting yourself is an act of rebellion (and power) Intuition isn’t magic—it’s a deep, internal guidance system that already exists inside you. The question is: are you listening? Connect with Hrund: Website: www.hrundgunnsteinsdottir.com TedTalk: https://www.ted.com/talks/hrund_gunnsteinsdottir_listen_to_your_intuition_it_can_help_you_navigate_the_future?utm_campaign=tedspread&utm_medium=referral&utm_source=tedcomshare Newsletter: https://hrundgunnsteinsdottir.com/blog/ LI: www.linkedin.com/in/hrundgunnsteinsdottir IG: https://www.instagram.com/hrundgunnsteinsdottir/ Book: InnSæi: Icelandic Wisdom for Turbulent Times Related Podcast Episodes: How To Breathe: Breathwork, Intuition and Flow State with Francesca Sipma | 267 VI4P - Know Who You Are (Chapter 4) Gentleness: Cultivating Compassion for Yourself and Others with Courtney Carver | 282 Share the Love: If you found this episode insightful, please share it with a friend, tag us on social media, and leave a review on your favorite podcast platform! 🔗 Subscribe & Review: Apple Podcasts | Spotify | Amazon Music Learn more about your ad choices. Visit megaphone.fm/adchoices…

Research To Practice | Oncology Videos

시리즈 홈•Feed

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

1540 에피소드

#Science #Medicine #Cancer #Neillove #Oncology #Researchtopractice #Fitness #Dr Neil Love #Video

Research To Practice | Oncology Videos

46 subscribers

updated 약 13시간 전

시리즈 홈•Feed

1540 에피소드

#Science #Medicine #Cancer #Neillove #Oncology #Researchtopractice #Fitness #Dr Neil Love #Video

All episodes

Research To Practice | Oncology Videos

1
Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture) 30:24

13 hours 전30:24

나중에 재생

리스트

30:24

Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics: Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00) Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax (7:03) Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35) Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28) Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease (15:52) Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12) Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor (19:38) Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment (22:15) Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13) Available data with epcoritamab monotherapy for R/R CLL (26:58) The emerging pharmacologic class of BTK degraders (29:04) CME information and select publications…

Research To Practice | Oncology Videos

1
Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel Therapies 42:34

1 day 전42:34

나중에 재생

리스트

42:34

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: EZH2 Inhibitors for Follicular Lymphoma (FL) (0:00) Bruton Tyrosine Kinase Inhibitors for FL (5:43) Anti-CD19 Antibodies for FL (9:40) Other Novel Agents Under Clinical Development for FL (18:50) Case: A woman in her early 80s with multiple comorbidities and relapsed FL (23:06) Case: A man in his early 40s with high-risk progressive FL that did not achieve deep remission with prior therapy (27:07) Case: A woman in her early 70s with rheumatoid arthritis and relapsed FL (33:46) CME information and select publications…

Research To Practice | Oncology Videos

1
Urothelial Bladder Cancer — Fourth Annual National General Medical Oncology Summit 49:02

2일 전49:02

나중에 재생

리스트

49:02

Featuring perspectives from Dr Shilpa Gupta and Dr Jonathan E Rosenberg, including the following topics: Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Gupta (0:00) Optimizing the Treatment of Metastatic UBC — Dr Rosenberg (21:52) CME information and select publications

Research To Practice | Oncology Videos

1
Pancreatic Cancer — Fourth Annual National General Medical Oncology Summit 49:14

3일 전49:14

나중에 재생

리스트

49:14

Featuring perspectives from Dr Paul E Oberstein and Dr Philip A Philip, including the following topics: Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Oberstein (0:00) Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr Philip(30:57) CME information and select publications…

Research To Practice | Oncology Videos

1
Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific Antibodies' 49:55

4일 전49:55

나중에 재생

리스트

49:55

Featuring an interview with Dr Jennifer Crombie, including the following topics: Overview of similarities and differences among CD20 x CD3 targeted bispecific antibodies for the treatment of lymphomas (0:00) Optimal integration of CD20 x CD3 bispecific antibodies into treatment algorithms for lymphomas (9:40) Case: A man in his late 60s with relapsed follicular lymphoma (FL) who received mosunetuzumab (23:52) Case: A man in his late 80s with transformed, double-hit diffuse large B-cell lymphoma (DLBCL) who received epcoritamab (28:46) Case: A woman in her early 70s with recurrent FL who received odronextamab on the ELM-1 trial (34:06) Case: A man in his early 80s with multiregimen-relapsed DLBCL who receives glofitamab (43:19) CME information and select publications…

Research To Practice | Oncology Videos

1
5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 17:35

5일 전17:35

나중에 재생

리스트

17:35

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00) Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00) Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25) Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57) Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5. CME information and select publications…

Research To Practice | Oncology Videos

1
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit 50:15

6일 전50:15

나중에 재생

리스트

50:15

Featuring perspectives from Dr Ramaswamy Govindan and Dr Stephen V Liu, including the following topics: Introduction (0:00) Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Mutation — Dr Govindan (4:04) First- and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation — Dr Liu (26:59) CME information and select publications…

Research To Practice | Oncology Videos

1
Colorectal Cancer — Fourth Annual National General Medical Oncology Summit 50:09

7일 전50:09

나중에 재생

리스트

50:09

Featuring perspectives from Dr Christopher Lieu and Dr Kanwal Raghav, including the following topics: Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Dr Lieu (0:00) Recent Advances in the Management of Metastatic CRC — Dr Raghav (32:58) CME information and select publications…

Research To Practice | Oncology Videos

1
Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy 37:09

8일 전37:09

나중에 재생

리스트

37:09

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00) Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50) Published Clinical Data Involving Axi-cel (10:24) Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34) Published Clinical Data Involving Tis-cel (19:47) Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43) Published Clinical Data Involving Liso-cel (26:05) Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48) Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35) Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59) CME information and select publications…

Research To Practice | Oncology Videos

1
Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances 1:00:00

9일 전1:00:00

나중에 재생

리스트

1:00:00

Featuring perspectives from Dr Emmanuel S Antonarakis and Prof Karim Fizazi, including the following topics: Introduction: Quality of Life (0:00) PARP Inhibition (PARPi) (7:15) M0 Disease (23:18) Metastatic Hormone-Sensitive Prostate Cancer (34:33) Radiopharmaceuticals (46:16) Other Novel Investigational Approaches for Metastatic Castration-Resistant Prostate Cancer (54:53) CME information and select publications…

Research To Practice | Oncology Videos

1
Prostate Cancer | Emmanuel S Antonarakis, MD 51:13

10일 전51:13

나중에 재생

리스트

51:13

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches — Emmanuel S Antonarakis, MD CME information and select publications

Research To Practice | Oncology Videos

1
Prostate Cancer | Professor Karim Fizazi, MD, PhD 32:35

11일 전32:35

나중에 재생

리스트

32:35

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer (PC) — Professor Karim Fizazi, MD, PhD CME information and select publications…

Research To Practice | Oncology Videos

1
Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology Summit 50:04

12일 전50:04

나중에 재생

리스트

50:04

Featuring perspectives from Dr Christopher Flower and Dr Krish Patel, including the following topics: Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Non-Hodgkin Lymphoma (NHL) — Dr Patel (0:00) Other Available and Emerging Novel Therapies for NHL — Dr Flowers (22:07) CME information and select publications…

Research To Practice | Oncology Videos

1
Gynecologic Cancers — Fourth Annual National General Medical Oncology Summit 48:42

14일 전48:42

나중에 재생

리스트

48:42

Featuring perspectives from Dr David M O’Malley and Dr Brian M Slomovitz, including the following topics: Ovarian Cancer; HER2-Directed Therapy for Advanced Gynecologic Cancers — Dr O'Malley (0:00) Endometrial Cancer and Cervical Cancer — Dr Slomovitz (23:38) CME information and select publications

Research To Practice | Oncology Videos

1
Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting 52:37

15일 전52:37

나중에 재생

리스트

52:37

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications…

Research To Practice | Oncology Videos

1
Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture) 37:30

15일 전37:30

나중에 재생

리스트

37:30

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications…

Research To Practice | Oncology Videos

1
Oncology Nursing Update: Prostate Cancer — Proceedings from the 2025 Annual ONS Congress 1:28:52

16일 전1:28:52

나중에 재생

리스트

1:28:52

Featuring perspectives from Dr Rahul Aggarwal, Ms Monica Averia, Ms Kathleen D Burns and Dr William K Oh, including the following topics: Introduction: Overview of Prostate Cancer (0:00) Recent Advances in the Treatment of Nonmetastatic Prostate Cancer (8:36) Treatment Approaches for Metastatic Hormone-Sensitive Prostate Cancer (30:01) Current Role of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (47:41) Current and Future Role of Radiopharmaceuticals in mCRPC (1:09:57) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Breast Cancer — Year in Review Series on Relevant New Datasets and Advances 59:31

17일 전59:31

나중에 재생

리스트

59:31

Featuring perspectives from Prof Rebecca A Dent and Dr Nancy U Lin, including the following topics: Introduction: A New Paradigm for Triple-Positive Breast Cancer? (0:00) CDK4/6 Inhibitors for HR-Positive, HER2-Negative Breast Cancer (10:06) Oral Selective Estrogen Receptor Degraders for HR-Positive, HER2-Negative Breast Cancer (21:17) Treatment of PIK3CA/PTEN/AKT-Mutated Breast Cancer (31:34) Antibody-Drug Conjugates (ADCs) for HR-Positive, HER2-Negative Breast Cancer (38:41) ADCs for HER2-Positive Breast Cancer (46:30) HER2-Targeting Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer (53:26) ADCs for Advanced Triple-Negative Breast Cancer (58:29) CME information and select publications…

Research To Practice | Oncology Videos

1
Breast Cancer | Nancy U Lin, MD 41:23

18일 전41:23

나중에 재생

리스트

41:23

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Breast Cancer | Faculty Presentation 2: HER2-Positive Breast Cancer and Triple-Negative Breast Cancer (TNBC) — Nancy U Lin, MD CME information and select publications

Research To Practice | Oncology Videos

1
Breast Cancer | Rebecca A Dent, MD, MSc'; 34:56

19일 전34:56

나중에 재생

리스트

34:56

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Breast Cancer | Faculty Presentation 1: HR-Positive Breast Cancer — Rebecca A Dent, MD, MSc CME information and select publications

Research To Practice | Oncology Videos

1
Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances 59:14

20일 전59:14

나중에 재생

리스트

59:14

Featuring perspectives from Dr Jennifer R Brown and Prof Paolo Ghia, including the following topics: Introduction: The Chronic Lymphocytic Leukemia (CLL) Experience — 2000 to 2025 (0:00) Current Therapy Options with Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (9:42) Role of Venetoclax in the Treatment of CLL (26:52) AMPLIFY Trial and Other Novel BTK Inhibitor and Bcl-2 Inhibitor Combination Strategies (32:29) Noncovalent BTK Inhibitor Pirtobrutinib (46:47) CAR T-Cell Therapy; Novel Agents (56:12) CME information and select publications…

Research To Practice | Oncology Videos

1
Chronic Lymphocytic Leukemia | Jennifer R Brown, MD, PhD 29:46

22일 전29:46

나중에 재생

리스트

29:46

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 2: Novel Agents and Combination Strategies — Jennifer R Brown, MD, PhD CME information and select publications

Research To Practice | Oncology Videos

1
Chronic Lymphocytic Leukemia | Paolo Ghia, MD, PhD 32:31

22일 전32:31

나중에 재생

리스트

32:31

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 1: Current Role of Covalent Bruton Tyrosine Kinase Inhibitors and Bcl-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL) — Paolo Ghia, MD, PhD CME information and select publications…

Research To Practice | Oncology Videos

1
For Oncology Nurses: Ovarian Cancer — Proceedings from the 2025 Annual ONS Congress 1:31:27

23일 전1:31:27

나중에 재생

리스트

1:31:27

Featuring perspectives from Ms Courtney Arn, Ms Jennifer Filipi, Dr David M O’Malley and Dr Shannon N Westin, including the following topics: Introduction: Overview of Ovarian Cancer (OC) Management (0:00) Genetic Testing for Newly Diagnosed Advanced OC (14:31) Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC (22:46) Other Available and Investigational Novel Strategies for OC (43:56) Current and Future Role of Mirvetuximab Soravtansine in OC Treatment (1:19:24) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Prostate Cancer — Fourth Annual National General Medical Oncology Summit 47:34

25일 전47:34

나중에 재생

리스트

47:34

Featuring perspectives from Dr Rahul Aggarwal and Dr William K Oh, including the following topics: Hormonal Therapy for Patients with Prostate Cancer — Dr Oh (0:00) Other Available and Emerging Therapeutic Approaches — Dr Aggarwal (27:14) CME information and select publications

Research To Practice | Oncology Videos

1
Immune Thrombocytopenia — A Roundtable Discussion on Current and Future Management Strategies 1:56:58

26일 전1:56:58

나중에 재생

리스트

1:56:58

Featuring slide presentations and related discussion from Dr Hanny Al-Samkari, Dr James B Bussel and Prof Nichola Cooper, including the following topics: Introduction (0:00) Clinical Manifestations and Initial Management of Immune Thrombocytopenia (ITP) — Dr Al-Samkari (10:24) Second- and Later-Line Therapies for ITP — Dr Bussel (1:00:51) Tolerability and Other Practical Considerations with Available Treatment Strategies for Persistent/Chronic ITP — Prof Cooper (1:28:08) CME information and select publications…

Research To Practice | Oncology Videos

1
Biliary Tract Cancers — Fourth Annual National General Medical Oncology Summit 48:55

28일 전48:55

나중에 재생

리스트

48:55

Featuring perspectives from Dr Mitesh J Borad and Dr Amit Mahipal, including the following topics: Introduction (0:00) Targeted Therapeutic Approaches for Patients with Biliary Tract Cancers (BTCs) — Dr Mahipal (4:59) Integration of Immune Checkpoint Inhibitors into Current BTC Management — Dr Borad (32:16) CME information and select publications…

Research To Practice | Oncology Videos

1
Oncology Nursing Update: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress 1:33:03

29일 전1:33:03

나중에 재생

리스트

1:33:03

Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (4:40) Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12:40) Role of ADCs for Patients with ER-Positive mBC (35:09) T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations (52:20) Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC (1:12:20) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy 52:53

29일 전52:53

나중에 재생

리스트

52:53

Featuring an interview with Dr Adam M Brufsky, including the following topics: Case: A woman in her early 50s with ER-positive, HER2-low de novo metastatic breast cancer (0:00) Case: A woman in her late 70s with ER-positive, HER2-low metastatic breast cancer after 5 years of an adjuvant aromatase inhibitor (6:52) Clinical Investigator Survey Results (10:05) CME information and select publications…

Research To Practice | Oncology Videos

1
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy (Companion… 32:02

4 weeks 전32:02

나중에 재생

리스트

32:02

Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics: Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00) Comparing safety profiles of CDK4/6 inhibitors (9:49) Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06) Real-world evidence with CDK4/6 inhibitors (27:31) CME information and select publications…

Research To Practice | Oncology Videos

1
Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates 44:21

5 weeks 전44:21

나중에 재생

리스트

44:21

Featuring an interview with Dr William K Oh, including the following topics: Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00) Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10) Radiopharmaceuticals for the treatment of mCRPC (16:53) Available data on cabozantinib for mCRPC (24:38) Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17) Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00) Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28) Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39) Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44) Data surrounding adjuvant immunotherapy for MIBC (38:07) Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44) Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06) Implementation of emerging data in the treatment landscape of UC (41:56) CME information and select publications…

Research To Practice | Oncology Videos

1
Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies 40:11

5 weeks 전40:11

나중에 재생

리스트

40:11

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00) Clinical Data Available with Mosunetuzumab for R/R FL (1:54) Clinical Data Available with Epcoritamab for R/R FL (4:54) Clinical Data Available with Odronextamab for R/R FL (6:53) Clinical Considerations in Selecting Among Available Bispecific Antibodies for R/R FL (8:34) Practical Considerations in the Administration of Bispecific Antibodies (15:21) The Role of Vaccinations in the Prevention of Infections for Patients Receiving Bispecific Antibodies (18:34) Ongoing Clinical Trials Evaluating Bispecific Antibodies for FL (21:34) Case: A man in his late 60s with refractory FL who received mosunetuzumab monotherapy (24:24) Case: A woman in her late 50s with relapsed FL who received third-line epcoritamab monotherapy (30:14) Case: A man in his late 80s with a long-standing history of FL who received odronextamab in combination with a second novel bispecific antibody (33:48) CME information and select publications…

Research To Practice | Oncology Videos

1
EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit 52:18

5 weeks 전52:18

나중에 재생

리스트

52:18

Featuring perspectives from Dr Jonathan Goldman and Dr Natasha B Leighl, including the following topics: Introduction (0:00) Current Management of Nonmetastatic and Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Prof Leighl (1:42) Promising Novel Agents in Clinical Development; EGFR Exon 20 Mutation-Positive NSCLC — Dr Goldman (37:25) CME information and select publications…

Research To Practice | Oncology Videos

1
HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit 1:39:35

5 weeks 전1:39:35

나중에 재생

리스트

1:39:35

Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics: Introduction (0:00) HER2-Positive Breast Cancer — Dr O’Shaughnessy (3:13) Triple-Negative Breast Cancer — Dr Bardia (32:56) Personalizing Adjuvant Therapy for Patients with HR-Positive Breast Cancer — Dr Borges (57:35) Current Role of CDK4/6 Inhibitors in the Localized Setting — Dr Burstein (1:25:15) CME information and select publications…

Research To Practice | Oncology Videos

1
Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2 58:21

5 weeks 전58:21

나중에 재생

리스트

58:21

Featuring an interview with Ms Amy Goodrich, including the following topics: Presentation and management of follicular lymphoma (FL) (0:00) Case: A woman in her late 70s with heavily pretreated disease experiences complete response to mosunetuzumab (24:41) Case: A man in his early 60s with extensive diffuse large B-cell lymphoma and short response to CAR-T is successfully bridged to allogeneic transplant with glofitamab (30:15) Case: A man in his late 50s with transformed FL has limited treatment options due to lack of social support (45:51) Effects of bispecific antibodies in follicular and diffuse large B-cell lymphoma (52:53) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Ovarian Cancer — Proceedings from a Session Held During the 2025 SGO Annual Meeting on Women’s Cancer® 1:29:33

5 weeks 전1:29:33

나중에 재생

리스트

1:29:33

Featuring perspectives from Dr Kathleen N Moore, Dr Ritu Salani, Dr Angeles Alvarez Secord and Dr Shannon N Westin, moderated by Dr Secord, including the following topics: Introduction (0:00) Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Westin (2:42) Management of Relapsed/Refractory OC — Dr Secord (23:06) Novel Investigational Therapies for Advanced OC — Dr Moore (46:55) Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC — Dr Salani (1:08:34) CME information and select publications…

Research To Practice | Oncology Videos

1
Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting 43:18

5 weeks 전43:18

나중에 재생

리스트

43:18

Featuring an interview with Dr Raajit K Rampal, including the following topics: Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00) Novel research strategies involving CDK4/6 inhibitors for MF (8:03) Implications of the JUMP study for clinical practice (10:00) Therapeutic switching strategies with JAK inhibitors for MF (12:17) Clinical rationale for the use of luspatercept and elritercept for MF (15:35) Emerging clinical data involving BET inhibitors for MF (16:57) Tolerability concerns with selinexor in patients with MF (20:01) Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32) Additional novel strategies under clinical investigation for MF (25:52) Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40) Management of polycythemia vera and essential thrombocythemia (34:27) General management principles for myeloproliferative neoplasms (37:53) CME information and select publications…

Research To Practice | Oncology Videos

1
Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture) 31:10

6 weeks 전31:10

나중에 재생

리스트

31:10

Featuring a slide presentation and related discussion from Dr Raajit K Rampal, including the following topics: Overview of the current JAK inhibitor landscape (0:00) Factors predicting clinical benefit in patients with myelofibrosis (MF) receiving ruxolitinib (3:02) Clinical data supporting the use of fedratinib after prior ruxolitinib for MF (9:17) Emerging clinical findings on pelabresib in combination with ruxolitinib for previously untreated MF (12:13) Available clinical data with novel BET inhibitors (15:00) Utility of selinexor in combination with ruxolitinib for MF previously treated with ruxolitinib (16:50) Emerging efficacy and safety findings reported with imetelstat for MF (18:57) Clinical findings reported with the MDM2 inhibitor navtemadlin for MF (21:15) Available clinical data with the TGF-beta inhibitor elritercept for MF (24:05) Other novel agents and strategies under investigation for MF (26:06) CME information and select publications…

Research To Practice | Oncology Videos

1
Sarcoma and Other Connective Tissue Neoplasms — Fourth Annual National General Medical Oncology Summit 51:15

6 weeks 전51:15

나중에 재생

리스트

51:15

Featuring perspectives from Dr Rashmi Chugh and Dr Richard F Riedel, including the following topics: Other Connective Tissue Neoplasms — Dr Chugh (0:00) Sarcoma — Dr Riedel (28:16) CME information and select publications

Research To Practice | Oncology Videos

1
HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit 1:59:30

6 weeks 전1:59:30

나중에 재생

리스트

1:59:30

Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics: Introduction (0:00) CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer (mBC) — Dr Borges (9:56) Targeting the PTEN/PI3K/AKT Pathway in HR-Positive mBC — Dr Burstein (35:20) Role of Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive mBC — Dr O’Shaughnessy (1:03:07) Antibody-Drug Conjugates for HR-Positive mBC — Dr Bardia (1:36:12) CME information and select publications…

Research To Practice | Oncology Videos

1
Chronic Lymphocytic Leukemia — Fourth Annual National General Medical Oncology Summit 50:12

6 weeks 전50:12

나중에 재생

리스트

50:12

Featuring perspectives from Dr Nicole Lamanna and Dr Kerry Rogers, including the following topics: Introduction (0:00) Current Role of Covalent Bruton Tyrosine Kinase and Bcl-2 Inhibitors in Managing Chronic Lymphocytic Leukemia — Dr Lamanna (10:55) Novel Agents and Combination Strategies — Dr Rogers (31:21) CME information and select publications…

Research To Practice | Oncology Videos

1
Neuroendocrine Tumors — Fourth Annual National General Medical Oncology Summit 50:16

6 weeks 전50:16

나중에 재생

리스트

50:16

Featuring perspectives from Dr Simron Singh and Dr Jonathan Strosberg, including the following topics: Introduction (0:00) Initial Therapy for Advanced Neuroendocrine Tumors (NETs) — Dr Singh (6:48) Management of Progressive Advanced NETs — Dr Strosberg (28:50) CME information and select publications…

Research To Practice | Oncology Videos

1
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor 57:29

6 weeks 전57:29

나중에 재생

리스트

57:29

Featuring an interview with Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:22) CME information and select publications…

Research To Practice | Oncology Videos

1
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor (Companion Faculty Lecture) 31:22

6 weeks 전31:22

나중에 재생

리스트

31:22

Featuring a slide presentation and related discussion from Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:31) CME information and select publications…

Research To Practice | Oncology Videos

1
Breast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial Updates 54:56

7 weeks 전54:56

나중에 재생

리스트

54:56

Featuring an interview with Dr Adrienne G Waks, including the following topics: The Phase III AFT-38 PATINA trial of palbociclib combined with anti-HER2 therapy for hormone receptor (HR)-positive/HER2-positive metastatic breast cancer (mBC) (0:00) Role of immunotherapy in the treatment of breast cancer (8:30) Defining ER-low breast cancer and identifying treatment approaches for this histologic subtype (15:55) Genomic testing approaches for patients with localized breast cancer and identification of candidates for treatment with adjuvant olaparib (19:37) Current role of anthracyclines in the treatment of localized breast cancer (31:17) Available and novel antibody-drug conjugates for the treatment of breast cancer (41:21) Palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for HR-positive, HER2-negative mBC (51:53) CME information and select publications…